(6-methyl-pyridin-3-yl)-acetic acid methyl ester | 90610-06-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (6-methyl-pyridin-3-yl)-acetic acid methyl ester
• 英文别名: methyl (6-methylpyridin-3-yl)acetate；Methyl-(2-methyl-5-pyridyl)acetate；Methyl-(2-methyl-5-pyridyl)acetat；Methyl 2-(6-methylpyridin-3-yl)acetate
• CAS: 90610-06-3
• 化学式: C₉H₁₁NO₂
• mdl: MFCD00274534
• 分子量: 165.192
• InChiKey: MXKHNJKVQCNCSH-UHFFFAOYSA-N

物化性质

• 沸点：
  242.4±25.0 °C(Predicted)
• 密度：
  1.088±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H320,H335

反应信息

• 作为反应物：
  描述：

  (6-methyl-pyridin-3-yl)-acetic acid methyl ester 在 sodium hydroxide 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 2.0h， 生成 2-(6-甲基吡啶-3-基)乙酸
  参考文献：
  名称：

  [EN] AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS
  [FR] AZÉTIDINES EN TANT QU'ANTAGONISTES DES RÉCEPTEURS H3 DE L'HISTAMINE

  摘要：

  该发明涉及式(I)的化合物，其中R、R1、m、n和X1至X3的含义如描述和权利要求中所述。所述化合物可用作组胺H3受体拮抗剂。该发明还涉及制药组合物，以及这些化合物的制备、生产和用作药物的方法。

  公开号：

  WO2010086403A1
• 作为产物：
  描述：

  甲醇 、 2-(6-甲基吡啶-3-基)乙腈 在 硫酸 作用下， 反应 16.0h， 生成 (6-methyl-pyridin-3-yl)-acetic acid methyl ester
  参考文献：
  名称：

  Discovery of novel phenethylpyridone derivatives as potent melanin-concentrating hormone 1 receptor antagonists

  摘要：

  Novel phenethylpyridone derivatives were identified as potent human melanin-concentrating hormone 1 receptor (MCH-1R) antagonists. A search for surrogates for the 4-(2-aminoethoxy) phenyl moiety of 1 resulted in discovery of 2-[4-(aminomethyl) phenyl] ethyl substructure as in 6a. Successive optimization of the right-hand moiety led to the identification of a number of potent derivatives. (C) 2009 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2009.07.023

文献信息

• NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALKANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALKANONE DERIVATIVES AND USE THEREOF AS p75 INHIBITORS
  申请人：BARONI Marco

  公开号：US20120245149A1

  公开（公告）日：2012-09-27

  The disclosure relates to (heterocycle-fused piperidine)-(piperazinyl)-1-alkanone derivatives and (heterocycle-fused pyrrolidine)-(piperazinyI)-1-alkanone derivatives of formula (I): wherein A, W, R2 and n are as defined in the disclosure, to the method of preparation thereof and the therapeutic use thereof.

  该公开涉及到式(I)的(杂环融合哌啶)-(哌嗪基)-1-烷酮衍生物和(杂环融合吡咯啉)-(哌嗪基)-1-烷酮衍生物： 其中A、W、R2和n如公开所定义，以及其制备方法和治疗用途。
• Oxadiazolopyridine Derivates for Use as Ghrelin O-Acyl Transferase (GOAT) Inhibitors
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20180037594A1

  公开（公告）日：2018-02-08

  The present invention relates to compounds of general formula I, wherein the groups R 1 , R 2 and n are defined as in claim 1 , which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.

  本发明涉及通式I的化合物，其中基团R1、R2和n的定义如权利要求书中所述，该化合物具有有价值的药理学特性，特别是结合到生长激素释放激素酰基转移酶（GOAT）并调节其活性。这些化合物适用于治疗和预防可能受该受体影响的疾病，如代谢性疾病，特别是肥胖症。
• DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS
  申请人：BARONI Marco

  公开号：US20110144116A1

  公开（公告）日：2011-06-16

  The present invention relates to derivatives of ((phenyl)-3,6-dihydropyridin-1-yl)(bridged piperazinyl)-1-alkanone derivatives and ((phenyl)-2,5-dihydropyrrol-1-yl) (bridged piperazinyl)-1-alkanone corresponding to Formula (I): in which the variables are as defined herein, to the preparation thereof and to the therapeutic use thereof.

  本发明涉及到((苯基)-3,6-二氢吡啶-1-基)(桥式哌嗪基)-1-烷酮衍生物和((苯基)-2,5-二氢吡咯-1-基)(桥式哌嗪基)-1-烷酮衍生物，对应于式(I)：其中变量如此处所定义，以及其制备和治疗用途。
• AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS
  申请人：Davenport Adam James

  公开号：US20120040952A1

  公开（公告）日：2012-02-16

  The invention relates to compounds of formula (I), wherein R, R 1 , m, n and X 1 to X 3 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

  该发明涉及式（I）的化合物，其中R、R1、m、n和X1至X3的含义如描述和权利要求中所述。所述化合物可用作组胺H3受体拮抗剂。该发明还涉及制药组合物、制备此类化合物以及作为药物的生产和使用。
• Substituted Heteroaryls
  申请人：Pfizer Inc.

  公开号：US20130165452A1

  公开（公告）日：2013-06-27

  The present invention provides Formula (1A) compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. X, Y, Z, R 1 , R 2 , R 3 , and R 4 are as described herein.

  本发明提供了作为葡萄糖激酶激活剂的Formula（1A）化合物；其制药组合物；以及治疗由葡萄糖激酶介导的疾病，疾病或病状的方法。其中X，Y，Z，R1，R2，R3和R4如本文所述。